SCHEMBL3143074

SCHEMBL3143074

CC(=O)c1cc(NCC(O)CNC(=O)C2=CC(Cl)=CCC2=S)ccc1N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.41
KDM4E B2RXH2 7/20 0.41
HTT P42858 5/20 0.41
RAB9A P51151 4/20 0.40
MAPT P10636 4/20 0.40
NPC1 O15118 2/20 0.40
GAA P10253 7/20 0.39
LMNA P02545 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 3/20 0.39
ALOX15 P16050 2/20 0.39
MAPK1 P28482 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3148099 0.92 GAA (0.39) ALDH1A1KDM4EHTTRAB9AMAPT
SCHEMBL3151531 0.88 LMNA (0.42) ALDH1A1KDM4EHTTRAB9AMAPT
SCHEMBL3152897 0.83 KDM4E (0.43) ALDH1A1KDM4EHTTRAB9AMAPT
SCHEMBL3146160 0.80 F10 (0.47)
SCHEMBL3156588 0.80 F10 (0.44)
SCHEMBL3148052 0.79 F10 (0.40)
SCHEMBL77772 0.79 F10 (0.49) ALDH1A1KDM4EHTTRAB9AMAPT
SCHEMBL3146428 0.79 F10 (0.45)
SCHEMBL3140868 0.79 TAAR1 (0.39) KDM4EMAPTSMN1; SMN2
SCHEMBL4557410 0.78 MAPT (0.43) ALDH1A1KDM4EHTTRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1922316-B1 BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK MODULATORS GLAXOSMITHKLINE LLC (US) 2010-03-03 EP disclosed
EP-2099453-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-09-16 EP disclosed
EP-1937271-A1 MICROANGIOPATHY TREATMENT AND PREVENTION Bayer HealthCare AG (DE) 2008-07-02 EP disclosed
WO-2008052671-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-08 WO disclosed
WO-2007042146-A1 MICROANGIOPATHY TREATMENT AND PREVENTION BAYER HEALTHCARE AG (DE) 2007-04-19 WO disclosed
EP-1526132-A2 Substituted oxazolidinone derivatives and their use as factor xa inhibitors Bayer HealthCare AG (DE) 2005-04-27 EP disclosed
WO-2001047919-A9 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AG (DE) 2002-12-19 WO disclosed